目的 比較佐米曲普坦片和鹽酸洛美利嗪膠囊治療偏頭痛的臨床療效。方法 選取2013年1月—2014年10月濱州醫(yī)學院煙臺附屬醫(yī)院神經(jīng)內科門診收治的偏頭痛患者110例,隨機分為對照組和治療組,每組各55例。對照組早晚飯后口服鹽酸洛美利嗪膠囊,5 mg/次,2次/d。治療組患者口服佐米曲普坦片,2.5 mg/次,1次/d。兩組均連續(xù)治療4周。觀察兩組的臨床療效,同時比較兩組治療前后視覺模擬(VAS)評分、頭痛發(fā)作頻率、24 h內頭痛緩解維持時間的變化。結果 治療后,對照組和治療組的總有效率分別為76.36%、94.55%,兩組比較差異具有統(tǒng)計學意義(P <0.05)。治療后,兩組患者VAS評分、患者頭痛發(fā)作頻率均較治療前顯著降低,24 h內頭痛緩解維持時間均顯著提高,同組治療前后差異具有統(tǒng)計學意義(P <0.05);且治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異具有統(tǒng)計學意義(P <0.05)。隨訪4周,對照組和治療組的復發(fā)率分別為14.55%、5.45%,兩組比較差異具有統(tǒng)計學意義(P <0.05)。結論 佐米曲普坦片治療偏頭痛療效顯著,且復發(fā)率較低,安全性高,有較好的應用和推廣價值。

Objective To compare the clinical effect of Zolmitriptan Tablets and Lomerizine Hydrochloride Capsules in treatment of migraine. MethodsPatients (110 cases) with migraine in Department of Neurology outpatient service of Yantai Affiliated Hospital of Binzhou Medical University from January 2013 to October 2014 were randomly divided into control and treatment groups, and each group had 55 cases. The patients in the control group were po administered with Lomerizine Hydrochloride Capsules after breakfast and dinner, 5 mg/time, twice daily. The patients in the treatment group were po administered with Zolmitriptan Tablets, 2.5 mg/time, once daily. Two groups were treated for four weeks. After treatment, the efficacy was evaluated, and the changes of VAS score, headache frequency, headache relief to maintain time within 24 h in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 76.36% and 94.55%, respectively, and there was difference between two groups (P < 0.05). After treatment, VAS score and headache frequency in two groups were significantly reduced, and headache relief to maintain time within 24 h was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Followed up for four weeks, the recurrence rate in the control and treatment groups were 14.55% and 5.45%, respectively, and there was difference between two groups (P < 0.05). Conclusion Zolmitriptan Tablets has obvious therapeutic effect in treatment of migraine with low recurrence rate and high safety, which has the good application and promotion value.